Synaffix B.V., a biotechnology company focused on enabling antibody-drug
conjugates (ADCs) with superior therapeutic index based on its
proprietary ADC technologies, announces that Shanghai Miracogen Inc., a
Chinese biotechnology company with a clinical-stage pipeline of ADCs,
has expanded its existing collaboration by taking a license to develop
and commercialize a second product candidate.
Under the terms of the agreement, Miracogen has been granted
non-exclusive rights to Synaffix’s proprietary GlycoConnect™ and
HydraSpace™ ADC technologies for use in this second clinical candidate.
Synaffix is eligible to receive upfront, milestone and royalty payments
tied to this new program. Further financial details were not disclosed.
The original agreement was announced
in April 2019, with Miracogen responsible for the research,
development, manufacturing and commercialization of its ADC product, and
Synaffix responsible for the manufacturing of components specifically
related to its proprietary ADC technologies.
Peter van de Sande, CEO of Synaffix said:
“This expansion of our licensing agreement has resulted from the rapid
and successful progression of Miracogen’s first ADC program with us and
our strong working relationship. With six announced ADCs now under
clinical or preclinical development based on Synaffix platform
technologies, this expansion serves as further testament to the maturity
of our proprietary ADC technologies.
“We look forward to continuing to work closely with Miracogen to develop
innovative ADCs with enhanced therapeutic indexes for the treatment of
cancer.”
Mary Hu, CEO of Shanghai Miracogen added:
“Having worked with Synaffix over the past year and having seen highly
positive results arising from the use of the GlycoConnect and HydraSpace
technologies, we decided to expand the license agreement into a second
ADC candidate. Using Synaffix’s platform, we hope to develop an
additional ADC product candidate with an enhanced therapeutic index, and
ultimately benefit cancer patients.”
Notes to Editors
About GlycoConnect™ and HydraSpace™
The clinical-stage GlycoConnect™ and HydraSpace™ technologies enable
best-in-class ADCs with significantly enhanced efficacy and
tolerability. GlycoConnect™ is the conjugation technology that exploits
the native glycan for site-specific and stable payload attachment.
HydraSpace™ is the compact and highly polar spacer technology. These
technologies can be applied directly to any existing antibody without
any protein sequence engineering and are compatible with all ADC payload
classes.
The growing experience of Synaffix and its collaboration partners
continues to confirm the ability of GlycoConnect™ and HydraSpace™ to
consistently generate ADCs that are more effective and better tolerated
when compared to the three major clinical-stage ADC conjugation
technologies.
About Synaffix B.V.
Synaffix B.V. is a Dutch biotechnology company that enables highly
competitive ADC product candidates using its clinical-stage,
site-specific ADC technology platform. In addition to GlycoConnect™ and
the ADC-enhancing HydraSpace™ technology, the extension of the platform
with toxSYN™ payloads provides a fully complimentary technology platform
that enables any company with an antibody to develop superior,
proprietary ADC products.
The Synaffix platform comes with an IND-ready CMC package to support a
rapid timeline to the clinic. Granted patents covering Synaffix’s
technology provide end-to-end protection of the platform technology as
well as resulting products through at least 2035. The business model of
Synaffix is target-specific technology out-licensing, as exemplified
through its existing deals with Shanghai Miracogen, Mersana Therapeutics
and ADC Therapeutics.
Synaffix is backed by a top tier, European, life science-focused
investor syndicate that includes Aravis, BioGeneration Ventures, BOM
Capital and M Ventures.
For more information, please visit the website at www.synaffix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005092/en/